Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Jan 27;11(1):00793-2024.
doi: 10.1183/23120541.00793-2024. eCollection 2025 Jan.

Occluding mucous airway plugs in patients with obstructive lung diseases: a new treatable trait?

Alvar Agustí  1   2   3   4 , Stefano Aliberti  5   6 , Francesco Blasi  7   8 , Marc Miravitlles  9 , Alberto Papi  10   11
Affiliations
Editorial

Occluding mucous airway plugs in patients with obstructive lung diseases: a new treatable trait?

Alvar Agustí et al. ERJ Open Res. .

Abstract

Identifying mucous plugs by chest CT should be considered carefully because it is potentially a treatable trait https://bit.ly/4gyJHFW.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: A. Agustí has received research support, lecture payments and/or advisory board honoraria from AZ, Chiesi, Gebro, GSK, Menarini, MSD, Sanofi and Zambon. Conflict of interest: S. Aliberti has received grants/research support from Insmed, Chiesi and Fisher & Paykel, and consulting fees from Insmed, Zambon, AstraZeneca, CSL Behring, Grifols, Fondazione Charta, Boehringer Ingelheim, Chiesi, Zcube, Menarini and GlaxoSmithKline. Conflict of interest: F. Blasi has received grants/research support from AstraZeneca, Chiesi, GlaxoSmithKline and Insmed, and consulting fees from GlaxoSmithKline, OM Pharma and Menarini. Conflict of interest: M. Miravitlles has received grants from Grifols paid to his institution; consulting fees from AstraZeneca, Atriva Therapeutics, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, CSL Behring, Inhibrx, Ferrer, Menarini, Mereo Biopharma, Spin Therapeutics, Specialty Therapeutics, ONO Pharma, Palobiofarma SL, Takeda, Novartis, Novo Nordisk, Sanofi, Zambon and Grifols; honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Menarini, Kamada, Takeda, Zambon, CSL Behring, Specialty Therapeutics, Janssen, Grifols and Novartis; support for attending meetings and/or travel from Novartis, Boehringer Ingelheim, Menarini and GlaxoSmithKline. Additionally, M. Miravitlles is a member of the Mereo data safety monitoring board. Conflict of interest: A. Papi has received grants/research support from Chiesi, AstraZeneca, GSK, BI, Pfizer, Teva and Sanofi; honoraria or consultation fees from Chiesi, AstraZeneca, GSK, BI, Menarini, Novartis, Zambon, Mundipharma, Teva, Sanofi, Edmond Pharma, IQVIA, MSD, Avillion and Elpen Pharmaceuticals.

Figures

FIGURE 1
FIGURE 1
Mechanisms of excess airway mucus in chronic obstructive respiratory disorders: a potentially treatable trait.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Allinson JP, Hardy R, Donaldson GC, et al. . The presence of chronic mucus hypersecretion across adult life in relation to chronic obstructive pulmonary disease development. Am J Respir Crit Care Med 2016; 193: 662–672. doi:10.1164/rccm.201511-2210OC - DOI - PMC - PubMed
    1. Hughes R, Rapsomaniki E, Janson C, et al. . Frequent productive cough: symptom burden and future exacerbation risk among patients with asthma and/or COPD in the NOVELTY study. Respir Med 2022; 200: 106921. doi:10.1016/j.rmed.2022.106921 - DOI - PubMed
    1. Chalmers JD, Polverino E, Crichton ML, et al. . Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis Registry (EMBARC). Lancet Respir Med 2023; 11: 637–649. doi:10.1016/S2213-2600(23)00093-0 - DOI - PubMed
    1. Shi L, Wei F, Ma T, et al. . Impact of radiographic bronchiectasis in COPD. Respir Care 2020; 65: 1561–1573. doi:10.4187/respcare.07390 - DOI - PubMed
    1. Martinez-Garcia MÁ, Faner R, Oscullo G, et al. . Chronic bronchial infection and incident cardiovascular events in chronic obstructive pulmonary disease patients: a long-term observational study. Respirology 2021; 26: 776–785. doi:10.1111/resp.14086 - DOI - PubMed

Publication types